NVE (NVEC) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
7 May, 2026Executive summary
Net income for the quarter rose 27% year-over-year to $4.93 million ($1.02 per diluted share), driven by a 34% increase in non-defense product sales and offsetting a decline in defense and contract R&D sales.
Total revenue for the quarter increased 5% year-over-year to $7.65 million, and 23% sequentially from the prior quarter.
Fiscal year revenue grew 1.8% to $26.3 million, with net income up 1% to $15.2 million ($3.14 per diluted share).
Major expansion completed, increasing capacity and capabilities, especially for wafer-level chip-scale packaging.
Announced a quarterly cash dividend of $1.00 per share, payable May 29, 2026.
Financial highlights
Gross margin for the quarter was 78%, slightly down from 79% in the prior year quarter.
Operating expenses decreased 19% year-over-year, with R&D down 26% and SG&A down 5%.
Operating income for Q4 was $4.73 million, up from $4.25 million year-over-year.
Fiscal year gross profit was $20.73 million, down from $21.64 million in the prior year.
Cash flow from operations for the year was $16.7 million, up 16% from the prior year.
Outlook and guidance
Management expressed confidence in continued revenue and earnings growth, citing strong performance for the second consecutive quarter.
Defense sales expected to increase significantly in fiscal 2027.
Contract R&D revenue also expected to rise in the coming year.
Optimism for continued product sales growth, supported by favorable semiconductor industry conditions and new products.
No specific revenue guidance provided, but management expresses confidence in future growth due to increased capacity and inventory.
Latest events from NVE
- Quarterly revenue up 23% and net income up 11%, with a $1.00 dividend announced.NVEC
Q3 202614 Apr 2026 - Revenue and net income declined, but gross margin and cash returns to shareholders remained strong.NVEC
Q1 20253 Feb 2026 - Gross margin rose to 86% as R&D revenue surged and a $1.00 dividend was declared.NVEC
Q2 202519 Jan 2026 - Revenue and net income fell, but gross margin improved to 84% and a dividend was declared.NVEC
Q3 20259 Jan 2026 - Maintained strong earnings, expanded R&D, and appointed a new director with medical expertise.NVEC
Proxy Filing1 Dec 2025 - Annual meeting to elect directors, approve pay, and ratify auditor, with focus on ESG and governance.NVEC
Proxy Filing1 Dec 2025 - Key votes on directors, executive pay, and auditor ratification, with strong governance and ESG focus.NVEC
Proxy Filing1 Dec 2025 - Annual Meeting to vote on directors, executive pay, and auditor ratification August 1, 2024.NVEC
Proxy Filing1 Dec 2025 - Shareholders receive updated proxy materials and online access for upcoming governance votes.NVEC
Proxy Filing1 Dec 2025